Pluri CDMO has over two decades of experience in cell therapy. Based in Israel, the company offers services in process and analytical development, process scale-up, validation, logistics, and automation. They offer a proprietary, scalable manufacturing platform that follows GMP for the culture of many cell types, including autologous and allogeneic products; primary human stem cells; immune cells; and gene-edited cells, including viral vector and CRISPR-modified cells. Pluri CDMO has advanced potential therapeutics from preclinical through phase I–III clinical development.